Valeria R. Fantin

AVEO Oncology (United States) — United States

Medicine · Health Sciences

41h-index19.4kcitations168works21.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cutaneous lymphoproliferative disorders research(22), T-cell and Retrovirus Studies(22), Lymphoma Diagnosis and Treatment(19), Cancer, Hypoxia, and Metabolism(19), Histone Deacetylase Inhibitors Research(15)

Publications168 total

Targeting BCMA in multiple myeloma with a trifunctional NK cell engager
Cell Reports Medicine·2026Open Access
Reprogramming CD22 CAR-T cells in vivo using CD8-targeted mRNA-LNPs to treat hematological malignancies
Molecular Therapy·2026
307 Enhanced therapeutic potential of NK cell-based combination therapies in preclinical cancer models
Regular and Young Investigator Award Abstracts·2025Open Access
Discovery of ORIC-533, an Orally Bioavailable CD73 Inhibitor That Maintains Activity in High AMP Environments to Reverse Tumor Immunosuppression
Journal of Medicinal Chemistry·2025
Abstract A030: Accelerating Therapeutic Discovery for Pediatric Cancer: Optimization of 80S Ribosome Inhibitors for T-Cell Acute Lymphoblastic Leukemia
Cancer Research·2025
Abstract 5635: In vivo assessment of a potent TEAD inhibitor in a panel of malignant mesothelioma PDX model
Cancer Research·2025
Abstract 33: Development of a humanized mouse model for γδT cells
Cancer Research·2025
Abstract 6119: Efficient generation of active CAR-T cells from healthy donors and lymphoma patients
Cancer Research·2025
Deep learning uncovers histological patterns of YAP1/TEAD activity related to disease aggressiveness in cancer patients
iScience·2024· 2 citedOpen Access
In Vitro and In Vivo Activity of a Lipid Nanoparticle System for the In Vivo Generation of CAR T Cells
Blood·2024· 4 citedOpen Access
The Combination of the Novel Trifunctional BCMA NK Cell Engager SAR445514 with IMiDs and Celmods Enhances Cytotoxicity Against Multiple Myeloma Cells As Compared to Single Agents
Blood·2024· 2 cited
Deep learning uncovers histological patterns of YAP1/TEAD activity related to disease aggressiveness in cancer patients
2024Open Access
Abstract 5234: TGF<i>beta</i>-conditioned K-NK cells are able to counter immune suppression in the tumor micro-environment
Cancer Research·2024
Abstract 2118: SGN-CEACAM5C/SAR445953, a novel topoisomerase I inhibitor antibody-drug conjugate targeting CEACAM5, has potent anti-tumor activity in CRC, PDAC, GC and lung cancer tumor models
Cancer Research·2024· 1 cited
Abstract 1334: Evaluation of NK cell combination therapies in mouse models of cancer
Cancer Research·2024
Natural killer cell therapies
Nature·2024· 357 citedOpen Access
Collaborative Innovations in Childhood Cancer Therapies
Handbook of experimental pharmacology·2024
Abstract 6378: An <i>in vitro</i> human CD8 T cell exhaustion model for the functional screening of immune checkpoint inhibitors
Cancer Research·2023· 1 cited
Abstract 4890: A novel topoisomerase I inhibitor antibody-drug conjugate targeting CEACAM5 has potent anti-tumor activity in colorectal cancer models
Cancer Research·2023· 1 cited
Data from Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
2023Open Access
page 1 of 9Next →

Frequent Co-authors

Shinsan M. Su(7), Philip Leder(6), Lenny Dang(5), Stefan Größ(5), Hyun Gyung Jang(5), Katharine Yen(5), Kimberly Straley(5), Victoria M. Richon(5), Tod Smeal(5), Susanna R. Keller(5), Gustav E. Lienhard(5), Mark Bittinger(4), Edward M. Driggers(4), Shengfang Jin(4), Patrick S. Ward(4), Craig B. Thompson(4), Matthew G. Vander Heiden(4), David P. Schenkein(4), Bryson D. Bennett(3), Robert M. Prins(3)